Hepatitis B Vaccine Responsiveness and Clinical Outcomes in HIV Controllers: e105591

Background Hepatitis B virus (HBV) vaccine responsiveness is associated with reduced risk of AIDS or death in HIV-infected individuals. Although HIV controllers (HIC) typically have favorable immunologic and clinical characteristics compared to non-controllers, vaccine responsiveness has not been st...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2014-08, Vol.9 (8)
Main Authors: Okulicz, Jason F, Mesner, Octavio, Ganesan, Anuradha, O'Bryan, Thomas A, Deiss, Robert G, Agan, Brian K
Format: Article
Language:English
Subjects:
Hepatitis B virus
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Hepatitis B virus (HBV) vaccine responsiveness is associated with reduced risk of AIDS or death in HIV-infected individuals. Although HIV controllers (HIC) typically have favorable immunologic and clinical characteristics compared to non-controllers, vaccine responsiveness has not been studied. Methods and Findings In the U.S. Military HIV Natural History Study, HBV vaccine response was defined as antibody to hepatitis B surface antigen (anti-HBs) greater than or equal to 10 IU/L after last vaccination. For determination of vaccine responsiveness, HIC (n = 44) and treatment-naive non-controllers (n = 476) were not on highly active antiretroviral therapy (HAART) when vaccinated while treated non-controllers (n = 284) received all HBV vaccine doses during viral load (VL)-suppressive HAART. Progression to AIDS or death was also compared for all HIC (n = 143) and non-controllers (n = 1566) with documented anti-HBs regardless of the timing of HBV vaccination. Positive vaccine responses were more common in HIC (65.9%) compared to HAART-naive non-controllers (36.6%; P
ISSN:1932-6203
DOI:10.1371/journal.pone.0105591